Fig. 2From: A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trialThe Cost-effectiveness Acceptability Curves for Serplulimab plus CF Strategy Compared to Placebo plus CF Strategy in the Overall Patients (A), Patients with PD-L1 Expression Level of 1 ≤ CPS < 10 (B), Patients with PD-L1 CPS ≥ 10 (C). Abbreviation: QALY, quality-adjusted life-year; CF, cisplatin and 5-fluorouracilBack to article page